Clinical Trials Browser

Phase 2/3 × tislelizumab × Other solid neoplasm × Clear all

NCT05809336 2023-04-12

Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors

Phase 2/3 Completed

Other solid neoplasm

Advanced Solid Tumor